Computer Assessment of Mild Cognitive Impairment (CAMCI)

描述（由申请人提供）：阿尔茨海默病（AD）在美国影响着400万人。65岁以上人群的患病率每5年翻一番。目前，临床前阿尔茨海默病的认知特征是通过标准的神经心理学评估来确定的，这种评估通常涉及一系列测试，通常需要2-3小时。我们建议开发一种简短（10分钟）的计算机化测试，可由患者在医生的检查室完成。拟议的基于计算机的轻度认知障碍评估（CAMCI）将以标准化的方式收集数据，同时简单，无威胁和用户友好，并将可靠地识别经历认知困难的老年人。行为测试将评估工作记忆、附带记忆和前瞻记忆、执行功能、语言和精神运动速度。初步试验结果表明，该测试可以在临床环境中进行，可以区分有或没有轻度认知障碍和有阿尔茨海默氏症风险的老年人。该项目的第一阶段将包括运行60名患者和4名护士，以收集测试管理的有效性和敏感性的数据，作为轻度认知障碍（MCI）和阿尔茨海默氏症的有效初始筛查。CAMCI是基于目前公认的精神状态评估和目前公认的临床前痴呆鉴定标准。这将为轻度认知障碍的结果提供有价值的信息，因为患者可以在间隔访问中跟踪他们的初级保健医生。最后，也是最重要的一点是，识别出处于痴呆症初期阶段的老年人，将允许在疾病的早期阶段进行治疗干预，从而减缓甚至阻止疾病的发展。最终目标是改善认知能力下降早期阶段患者的生活质量，并通过防止进一步下降来降低医疗保健费用。为MCI和AD提供更好的诊断仪器是一个迫切的需求和商业上可行的市场。

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) affects 4 million people in the US. The prevalence doubles every five years beyond age 65. At present, the cognitive features of preclinical AD are identified through standard neuropsychological assessment that typically involves the administration of a battery of tests, often taking 2-3 hours. We propose to develop a brief (10 minute) computerized test that can be completed by the patient in a physician's examining room. The proposed Computer-based Assessment of Mild Cognitive Impairment (CAMCI), will collect data in a standardized fashion while being simple, non-threatening and user-friendly and will reliably identify older individuals experiencing cognitive difficulties. The behavioral tests will assess working memory, incidental memory and prospective memory, executive function, language and psychomotor speed. Initial pilot results show that the test can be administered in a clinical setting and can discriminate between older individuals with and without mild cognitive impairment and at risk for Alzheimer's. The Phase I of the project will involve running 60 patients and 4 nurses to collect data on the effectiveness of the test administration and sensitivity as an effective initial screen for mild cognitive impairment (MCI) and Alzheimer's. The CAMCI is based on currently accepted mental status assessments and currently accepted criteria for the identification of preclinical dementia. This will provide valuable information as to the outcome of mild cognitive impairment as patients can be tracked over interval visits to their primary care physician. Finally, and most important, identifying older people who are in the very beginning stages of a dementing illness will allow therapeutic intervention in the earliest stages of the disease, which, in turn, will slow or even prevent the progression of the disease. The ultimate goal is to improve the quality of life of people in the early stages of cognitive decline and to reduce health care costs by preventing further decline. There is a critical need and commercially viable market to provide better diagnostic instruments for MCI and AD.